The safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab, a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer

CD73 has emerged as a promising immuno-oncology target and is implicated in tumor resistance to checkpoint immunotherapy (CPI). Uliledlimab is a differentiated anti-CD73 antibody acting by an intra-dimer binding mode through the C-terminal domain as analyzed by cryo EM structure. Uliledlimab can achieve complete inhibition of CD73 activity with no hook effect as compared with other CD73 antibody. The present phase 1 clinical trial is designed to assess the safety, pharmacokinetic and pharmacodynamic (PK/PD) relationships and tumor biomarker analysis in correlation with clinical activity of uliledlimab as a monotherapy (3-week run-in) followed by combination therapy with atezolizumab in patients with solid tumors.